Table 2.

Summary of patient characteristics

Pt IDSexAge, yCTCL subtypeCurrent therapyPrevious therapy
1M73FMFECPNone
2M84SSBrentuximab, vorinostatPUVA, ECP, vorinostat, MTX, bexarotene, IFNα-2b, romidepsin, gemcitabine/doxorubicin, alemtuzumab
3M66SSECPNB-UVB, topical steroids
4M85SSECPTopical steroids
5F71SSGemcitabineECP, bexarotene, topical steroids, IFNα-2b, vorinostat, romidepsin, belinostat
6M73SSPralatrexateRomidepsin, ECP, bexarotene, topical steroids
7F61SSECP, bexaroteneTopical steroids, phototherapy
8M77SSRomidepsin, vorinostatECP, NB-UVB
9M70SSPralatrexateRomidepsin, vorinostat, mechlorethamine, ECP
10M71MFECP, bexaroteneNB-UVB, topical steroids
11F79SSECP, bexarotene, vorinostat, INFα-2bTopical steroids
12F64SSECP, bexaroteneTopical steroids
13F76SSECPNone
14M61MFECP, NB-UVBNone
15M67SSECP, bexaroteneNone
16F40FMFECP, bexaroteneNB-UVB, TSEBT
17M66SSECP, bexarotene, NB-UVB, topical steroidsNone
18F64MFECP, bexarotene, IFNα-2b, IFNγ-1bNone
19M87MFECPMTX, bexarotene, topical steroids
20M85MFECP, bexarotene, NB-UVBTopical steroids
21M70MF (V)EPOCHNone
22M77MFECP, bexaroteneNB-UVB, topical steroids
23M52MFGemcitabineNB-UVB, bexarotene, vorinostat, ECP, IFNα-2b, romidepsin,
24F62MFECP, bexarotene, NB-UVB, mechlorethamineTopical steroids
25M62MFECP, bexaroteneTopical steroids
  • ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; F, female; FMF, folliculotropic MF; IFN, interferon; M, male; MF, mycosis fungoides; MTX, methotrexate; NB-UVB, narrow band UV-B; PUVA, psoralen UV light A; SS, Sézary syndrome; TSEBT, total body electron beam therapy; V, visceral involvement.